SCHEMBL2999394

SCHEMBL2999394

O=C1C(Cc2c(Cl)cc(C(F)(F)F)cc2Cl)CCN1[C@H]1CC[C@@H](O)CC1

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 3/20 0.38
RORC P51449 3/20 0.33
P2RX7 Q99572 1/20 0.32
FFAR4 Q5NUL3 1/20 0.32
MRGPRX4 Q96LA9 1/20 0.32
POLB P06746 1/20 0.31
POLQ O75417 1/20 0.31
MEN1 O00255 2/20 0.31
ALDH1A1 P00352 2/20 0.31
KMT2A Q03164 2/20 0.31
LMNA P02545 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
NR3C1 P04150 1/20 0.31
MAPT P10636 1/20 0.31
EGFR P00533 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2999397 1.00 HSD11B1 (0.38) HSD11B1RORCP2RX7FFAR4MRGPRX4
SCHEMBL3001286 0.87 HSD11B1 (0.42) HSD11B1P2RX7MEN1KMT2AMAPT
SCHEMBL2995492 0.87 HSD11B1 (0.42) HSD11B1P2RX7MEN1KMT2AMAPT
SCHEMBL2995921 0.85 HSD11B1 (0.41) HSD11B1
SCHEMBL2993384 0.85 HSD11B1 (0.41) HSD11B1
SCHEMBL2989122 0.82 HSD11B1 (0.48) HSD11B1P2RX7POLBMEN1ALDH1A1
SCHEMBL2989117 0.82 HSD11B1 (0.48) HSD11B1P2RX7POLBMEN1ALDH1A1
SCHEMBL4514552 0.82 HSD11B1 (0.48) HSD11B1P2RX7POLBMEN1ALDH1A1
SCHEMBL2994422 0.81 HSD11B1 (0.38) HSD11B1FFAR4ALDH1A1LMNASMN1; SMN2
SCHEMBL2997454 0.81 HSD11B1 (0.38) HSD11B1FFAR4ALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100184764-A1 CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2010-07-22 US claimed
EP-1807072-B1 CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2009-01-07 EP claimed
US-20080275043-A1 Cycloalkyl Lactam Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase 1 ELI LILLY AND COMPANY 2008-11-06 US claimed
EP-1807072-B1 CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2009-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275043-A1 Cycloalkyl Lactam Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase 1 HSD11B1, HSDL2, HSD17B1 HSD11B1 1/4885RORC 2020/4885P2RX7 3884/4885
US-20100184764-A1 CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD17B1, HSD3B1 HSD11B1 1/4885RORC 1508/4885P2RX7 4250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.